uniQure had its Relative Strength (RS) Rating upgraded from 85 to 99 Wednesday.
IBD's proprietary rating tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
While the stock is not near a proper buy point right now, see if it manages to form and break out from a proper consolidation.
The company showed 0% EPS growth last quarter. Sales gains came in at 62%.
uniQure earns the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
